IL5 and eosinophilic granulomatosis with polyangiitis: The biologics era has led to an increase in the use of anti-IL-5 therapies and RTX, which have both demonstrated promising cardiac outcomes in EGPA whilst exhibiting potential to reduce the significant long-term glucocorticoid dependence in these patients.